DK2917210T3 - Alk kinase-inhibitorer - Google Patents
Alk kinase-inhibitorer Download PDFInfo
- Publication number
- DK2917210T3 DK2917210T3 DK13853072.0T DK13853072T DK2917210T3 DK 2917210 T3 DK2917210 T3 DK 2917210T3 DK 13853072 T DK13853072 T DK 13853072T DK 2917210 T3 DK2917210 T3 DK 2917210T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitors
- alk kinase
- alk
- inhibitors
- kinase
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723099P | 2012-11-06 | 2012-11-06 | |
| PCT/CN2013/086571 WO2014071832A1 (en) | 2012-11-06 | 2013-11-05 | Alk kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2917210T3 true DK2917210T3 (da) | 2019-05-27 |
Family
ID=50622903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13853072.0T DK2917210T3 (da) | 2012-11-06 | 2013-11-05 | Alk kinase-inhibitorer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9206166B2 (da) |
| EP (1) | EP2917210B1 (da) |
| JP (2) | JP6359020B6 (da) |
| KR (1) | KR102156398B1 (da) |
| CN (1) | CN104854101B (da) |
| AU (1) | AU2013344049B2 (da) |
| BR (1) | BR112015010221B1 (da) |
| CA (1) | CA2890006C (da) |
| DK (1) | DK2917210T3 (da) |
| ES (1) | ES2728008T3 (da) |
| RU (1) | RU2675850C2 (da) |
| WO (1) | WO2014071832A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890006C (en) * | 2012-11-06 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
| CN105085550B (zh) * | 2014-05-21 | 2017-05-24 | 海门慧聚药业有限公司 | 一类alk激酶抑制剂及其制备方法 |
| CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
| CN105622520A (zh) * | 2014-08-25 | 2016-06-01 | 上海博悦生物科技有限公司 | 一种治疗非小细胞肺癌药物色瑞替尼(Ceritinib)的新中间体及其制备方法 |
| WO2016040882A1 (en) * | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| US10011592B2 (en) | 2014-09-29 | 2018-07-03 | Xuanzhu Pharma Co., Ltd. | Polycyclic inhibitor of anaplastic lymphoma kinase |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| CN106146478B (zh) * | 2015-04-10 | 2019-07-16 | 海南轩竹医药科技有限公司 | 三嗪衍生物类间变性淋巴瘤激酶抑制剂 |
| CN104892526A (zh) * | 2015-06-17 | 2015-09-09 | 药源药物化学（上海）有限公司 | 一种2,5-二氯-n-(2-(异丙基磺酰基)苯基)嘧啶-4-胺的制备方法 |
| CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
| CN109071512A (zh) * | 2016-02-03 | 2018-12-21 | 重庆复创医药研究有限公司 | 作为激酶抑制剂的含磷化合物 |
| WO2018001251A1 (zh) * | 2016-06-27 | 2018-01-04 | 杭州雷索药业有限公司 | 苯并呋喃吡唑胺类蛋白激酶抑制剂 |
| CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| TWI798334B (zh) | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| CN112313232B (zh) * | 2018-05-02 | 2024-03-08 | Jw中外制药公司 | 新型杂环衍生物 |
| WO2019245038A1 (ja) | 2018-06-22 | 2019-12-26 | 株式会社Ｊｕｎｔｅｎ Ｂｉｏ | 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法 |
| TWI832868B (zh) | 2018-06-22 | 2024-02-21 | 日商順天生化股份有限公司 | 用於誘發感染性免疫耐受之組合物 |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| KR102168179B1 (ko) | 2019-10-31 | 2020-10-20 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| CN121712763A (zh) * | 2023-08-18 | 2026-03-20 | 复星万邦(江苏)医药集团有限公司 | 一种alk抑制剂的结晶形态 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2400477C2 (ru) * | 2003-03-14 | 2010-09-27 | Новартис Аг | 2,4-ди(фениламино)пиримидины, применимые при лечении неопластических заболеваний, воспалительных нарушений и нарушений иммунной системы |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| GB0319227D0 (en) * | 2003-08-15 | 2003-09-17 | Novartis Ag | Organic compounds |
| TWI378923B (en) * | 2003-08-15 | 2012-12-11 | Novartis Ag | Pyrimidine derivatives |
| CA2553785C (en) * | 2004-02-14 | 2011-02-08 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| BRPI0619424B1 (pt) * | 2005-12-05 | 2022-02-08 | Pfizer Products Inc | Uso de inibidores c-met/hgfrs para a fabricação de medicamentos |
| TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| US20080033412A1 (en) * | 2006-08-01 | 2008-02-07 | Harry Thomas Whelan | System and method for convergent light therapy having controllable dosimetry |
| ES2555803T3 (es) * | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| BRPI0722383A2 (pt) * | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
| WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| RU2472797C2 (ru) * | 2007-08-08 | 2013-01-20 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| WO2009032668A2 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
| TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| UY31750A (es) * | 2008-04-07 | 2009-12-14 | Irm Llc | Compuestos y composiciones como inhibidores de quinasa |
| EP2300469B1 (en) | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| EP2300013B2 (en) * | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| EP2331526A2 (en) | 2008-06-25 | 2011-06-15 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
| JP5364159B2 (ja) * | 2009-05-08 | 2013-12-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| EP2459558A2 (en) | 2009-07-30 | 2012-06-06 | Irm Llc | Compounds and compositions as syk kinase inhibitors |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| AU2010294209A1 (en) | 2009-09-10 | 2012-03-29 | Irm Llc | Ether derivatives of bicyclic heteroaryls |
| PH12013501254A1 (en) | 2010-12-17 | 2016-07-29 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| HUE025395T2 (en) | 2011-02-02 | 2016-02-29 | Novartis Ag | Methods using ALK inhibitors |
| CA2890006C (en) * | 2012-11-06 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
-
2013
- 2013-11-05 CA CA2890006A patent/CA2890006C/en active Active
- 2013-11-05 EP EP13853072.0A patent/EP2917210B1/en active Active
- 2013-11-05 US US14/071,953 patent/US9206166B2/en not_active Expired - Fee Related
- 2013-11-05 RU RU2015121374A patent/RU2675850C2/ru active
- 2013-11-05 KR KR1020157014984A patent/KR102156398B1/ko active Active
- 2013-11-05 ES ES13853072T patent/ES2728008T3/es active Active
- 2013-11-05 JP JP2015540039A patent/JP6359020B6/ja active Active
- 2013-11-05 DK DK13853072.0T patent/DK2917210T3/da active
- 2013-11-05 BR BR112015010221-2A patent/BR112015010221B1/pt active IP Right Grant
- 2013-11-05 WO PCT/CN2013/086571 patent/WO2014071832A1/en not_active Ceased
- 2013-11-05 CN CN201380058088.6A patent/CN104854101B/zh active Active
- 2013-11-05 AU AU2013344049A patent/AU2013344049B2/en active Active
-
2015
- 2015-10-29 US US14/926,729 patent/US9567342B2/en not_active Expired - Fee Related
-
2018
- 2018-04-10 JP JP2018075512A patent/JP6570001B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104854101B (zh) | 2018-05-01 |
| JP2018119003A (ja) | 2018-08-02 |
| KR102156398B1 (ko) | 2020-09-15 |
| JP6359020B2 (ja) | 2018-07-18 |
| JP2015535266A (ja) | 2015-12-10 |
| KR20150093687A (ko) | 2015-08-18 |
| CA2890006C (en) | 2021-11-23 |
| US9206166B2 (en) | 2015-12-08 |
| JP6570001B2 (ja) | 2019-09-04 |
| EP2917210B1 (en) | 2019-02-27 |
| WO2014071832A1 (en) | 2014-05-15 |
| US9567342B2 (en) | 2017-02-14 |
| BR112015010221A2 (pt) | 2017-07-11 |
| US20140128387A1 (en) | 2014-05-08 |
| CN104854101A (zh) | 2015-08-19 |
| ES2728008T3 (es) | 2019-10-21 |
| EP2917210A4 (en) | 2016-05-25 |
| AU2013344049A1 (en) | 2015-07-02 |
| EP2917210A1 (en) | 2015-09-16 |
| RU2675850C2 (ru) | 2018-12-25 |
| BR112015010221B1 (pt) | 2022-09-13 |
| AU2013344049B2 (en) | 2017-12-21 |
| US20160046638A1 (en) | 2016-02-18 |
| JP6359020B6 (ja) | 2018-08-15 |
| RU2015121374A (ru) | 2016-12-27 |
| CA2890006A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1006I2 (fr) | Inhibiteurs de pyrazolyl-quinoxaline kinase | |
| EP2917210A4 (en) | KINASE INHIBITORS | |
| DK2903618T3 (da) | Rho-kinase-inhibitorer | |
| LT3181567T (lt) | Pirazolpirimidino junginiai kaip kinazės slopikliai | |
| DK2710007T3 (da) | Kinasehæmmere | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| DK2895484T3 (da) | Glucosylceramidsynthase-inhibitorer | |
| CO6970602A2 (es) | Inhibidores de quinasa | |
| DK3321262T3 (da) | Serin-/threoninkinasehæmmere | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| IL230561A0 (en) | Inhibitors of bruton's tyrosine kinsae | |
| HUE040055T2 (hu) | RET inhibitor | |
| HUE039897T2 (hu) | Pirimidinil tirozin kináz inhibitorok | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| BR112015005361A2 (pt) | inibidores de tirosina quinase de bruton | |
| EP2863748A4 (en) | 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN | |
| ME02985B (me) | Prolekovi inhibitora amino-hinazolinske kinaze | |
| BR112014033056A2 (pt) | inibidores da proteína quinase | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| EP2968358A4 (en) | NOVEL CHOLINKINASE INHIBITORS | |
| SMT201600357B (it) | Inibitori di iap | |
| CO6990735A2 (es) | Inhibidores de pirazina cinasa | |
| BR112014029718A2 (pt) | inibidores da proteína quinase | |
| EP2847201A4 (en) | 6-oxo-purin-phosphoribosyl INHIBITORS | |
| IL242623A0 (en) | Pyrrolotriazines as alk inhibitors |